Sugi Predict

Sugi Predict / Compounds / SCHEMBL6552997

SCHEMBL6552997

SCHEMBL6552997

CC1(C)CC(=O)c2ccc(Br)cc2O1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.67
▸ KDM4E B2RXH2 3/20 0.67
▸ MAOB P27338 11/20 0.64
▸ MAPT P10636 2/20 0.54
▸ HTR2A P28223 1/20 0.52
▸ HTR2C P28335 1/20 0.52
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ PDE4B Q07343 1/20 0.47
▸ GAA P10253 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ GLA P06280 1/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MALT1 Q9UDY8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29640611 1.00 ALDH1A1 (0.67) ALDH1A1KDM4EMAOBMAPTHTR2A
SCHEMBL1821389 0.87 MAPT (0.71) ALDH1A1KDM4EMAOBMAPTNPC1
SCHEMBL6385719 0.81 ALDH1A1 (0.69) ALDH1A1KDM4EMAOBMAPTNPC1
SCHEMBL4728857 0.81 KDM4E (0.69) ALDH1A1KDM4EMAOBMAPTHTR2C
SCHEMBL1983108 0.80 ALDH1A1 (1.00) ALDH1A1KDM4EMAOBMAPTHTR2C
SCHEMBL1569957 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EMAOBMAPTNPC1
SCHEMBL4727223 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EMAOBMAPTNPC1
SCHEMBL2319848 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EMAOBMAPTNPC1
SCHEMBL29922134 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EMAOBMAPTNPC1
SCHEMBL29920457 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EMAOBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 — — US disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
EP-4626865-A1 CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS Protego Biopharma, Inc. (US) 2025-10-08 — — EP disclosed
US-20250042911-A1 NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF SPARK BIOPHARMA, INC. (KR) 2025-02-06 — — US disclosed
WO-2024118810-A1 CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS PROTEGO BIOPHARMA, INC. (US) 2024-06-06 — — WO disclosed
EP-4365175-A1 NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF Spark Biopharma, Inc. (KR) 2024-05-08 — — EP disclosed
CN-117897386-A Benzopyran derivatives and uses thereof 斯帕克生物制药有限公司 2024-04-16 — — CN disclosed
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 — — US disclosed
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-09-14 — — US disclosed
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-09-14 — — US disclosed
WO-2012110860-A1 TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-08-23 — — WO disclosed
EP-1388534-A2 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors Allergan, Inc. (US) 2004-02-11 — — EP disclosed
EP-1117628-B1 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS ALLERGAN INC (US) 2003-11-19 — — EP disclosed
US-20020082264-A1 Medicaments for viral diseases BAYER AKTIENGESELLSCHAFT (DE) 2002-06-27 — — US disclosed
US-6403638-B1 COMPOUND FOR USE IN TREATING SKIN DISEASES AND DISORDERS, AND FOR TREATING HYPERVITAMINOSIS A SYNDROME ALLERGAN SALES, INC. 2002-06-11 — — US disclosed
WO-2002020509-A2 MEDICAMENTS AGAINST VIRAL INFECTIONS BAYER AKTIENGESELLSCHAFT (DE) 2002-03-14 — — WO disclosed
WO-2001070662-A2 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS ALLERGAN , INC. (US) 2001-09-27 — — WO disclosed
EP-1117628-A1 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS Allergan Sales, Inc. (US) 2001-07-25 — — EP disclosed
US-6147224-A 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors ALLERGAN SALES, INC. (US) 2000-11-14 — — US disclosed
WO-2000020370-A1 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS ALLERGAN SALES, INC. (US) 2000-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082264-A1 Medicaments for viral diseases IRF3, STING1, EIF2AK2 ALDH1A1 3678/4885KDM4E 4065/4885MAOB 1941/4885
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 ALDH1A1 2837/4885KDM4E 1832/4885MAOB 2174/4885
US-20250042911-A1 NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF MYD88, MYADM, CD14 ALDH1A1 2146/4885KDM4E 588/4885MAOB 3668/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 ALDH1A1 1006/4885KDM4E 2752/4885MAOB 3044/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 ALDH1A1 3781/4885KDM4E 44/4885MAOB 3338/4885
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT8 ALDH1A1 4003/4885KDM4E 57/4885MAOB 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.